Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Hodgkin's Lymphoma in a Man with Dilated Cardiomyopathy and Paraneoplastic Ataxia: A Therapeutical Challenge.

Abruzzese E, Trawinska MM, Gaspardone A, Morocutti A, de Fabritiis P.

Hematol Rep. 2017 Jun 28;9(2):6944. doi: 10.4081/hr.2017.6944. eCollection 2017 Jun 1.

2.

Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.

Olivieri J, Perna GP, Bocci C, Montevecchi C, Olivieri A, Leoni P, Gini G.

Oncologist. 2017 Apr;22(4):422-431. doi: 10.1634/theoncologist.2016-0289. Epub 2017 Mar 8.

PMID:
28275118
3.

Cardiotoxicity of anthracycline therapy: current perspectives.

Valcovici M, Andrica F, Serban C, Dragan S.

Arch Med Sci. 2016 Apr 1;12(2):428-35. doi: 10.5114/aoms.2016.59270. Epub 2016 Apr 12.

4.

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.

Spallarossa P, Maurea N, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S84-92. doi: 10.2459/JCM.0000000000000381.

5.

Randomised controlled trial of a home-based physical activity intervention in breast cancer survivors.

Lahart IM, Metsios GS, Nevill AM, Kitas GD, Carmichael AR.

BMC Cancer. 2016 Mar 17;16:234. doi: 10.1186/s12885-016-2258-5.

6.

Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors.

Leger KJ, Cushing-Haugen K, Hansen JA, Fan W, Leisenring WM, Martin PJ, Zhao LP, Chow EJ.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1094-101. doi: 10.1016/j.bbmt.2016.02.017. Epub 2016 Mar 8.

7.

Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.

Feijen EA, Leisenring WM, Stratton KL, Ness KK, van der Pal HJ, Caron HN, Armstrong GT, Green DM, Hudson MM, Oeffinger KC, Robison LL, Stovall M, Kremer LC, Chow EJ.

J Clin Oncol. 2015 Nov 10;33(32):3774-80. doi: 10.1200/JCO.2015.61.5187. Epub 2015 Aug 24.

8.

Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.

Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Constine LS, Freyer DR, Lipshultz SE, Armenian SH.

J Clin Oncol. 2015 Aug 20;33(24):2639-45. doi: 10.1200/JCO.2014.59.4473. Epub 2015 May 26.

9.

The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review.

Conway A, McCarthy AL, Lawrence P, Clark RA.

BMC Cancer. 2015 May 7;15:366. doi: 10.1186/s12885-015-1407-6. Review.

10.

Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, Nathan PC, Tissing WJ, Shankar S, Sieswerda E, Skinner R, Steinberger J, van Dalen EC, van der Pal H, Wallace WH, Levitt G, Kremer LC; International Late Effects of Childhood Cancer Guideline Harmonization Group.

Lancet Oncol. 2015 Mar;16(3):e123-36. doi: 10.1016/S1470-2045(14)70409-7. Review.

11.

Individual prediction of heart failure among childhood cancer survivors.

Chow EJ, Chen Y, Kremer LC, Breslow NE, Hudson MM, Armstrong GT, Border WL, Feijen EA, Green DM, Meacham LR, Meeske KA, Mulrooney DA, Ness KK, Oeffinger KC, Sklar CA, Stovall M, van der Pal HJ, Weathers RE, Robison LL, Yasui Y.

J Clin Oncol. 2015 Feb 10;33(5):394-402. doi: 10.1200/JCO.2014.56.1373. Epub 2014 Oct 6.

12.

Cardiac effects of anticancer therapy in the elderly.

Accordino MK, Neugut AI, Hershman DL.

J Clin Oncol. 2014 Aug 20;32(24):2654-61. doi: 10.1200/JCO.2013.55.0459. Epub 2014 Jul 28. Review.

13.

Knockdown of TRPM8 suppresses cancer malignancy and enhances epirubicin-induced apoptosis in human osteosarcoma cells.

Wang Y, Yang Z, Meng Z, Cao H, Zhu G, Liu T, Wang X.

Int J Biol Sci. 2013 Dec 22;10(1):90-102. doi: 10.7150/ijbs.7738. eCollection 2013.

14.

Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease.

Armenian SH, Sun CL, Vase T, Ness KK, Blum E, Francisco L, Venkataraman K, Samoa R, Wong FL, Forman SJ, Bhatia S.

Blood. 2012 Nov 29;120(23):4505-12. doi: 10.1182/blood-2012-06-437178. Epub 2012 Oct 3.

15.

Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation.

Armenian SH, Sun CL, Shannon T, Mills G, Francisco L, Venkataraman K, Wong FL, Forman SJ, Bhatia S.

Blood. 2011 Dec 1;118(23):6023-9. doi: 10.1182/blood-2011-06-358226. Epub 2011 Oct 5.

16.

Cardiovascular complications of breast cancer therapy in older adults.

Shenoy C, Klem I, Crowley AL, Patel MR, Winchester MA, Owusu C, Kimmick GG.

Oncologist. 2011;16(8):1138-43. doi: 10.1634/theoncologist.2010-0348. Epub 2011 Jul 7. Review.

17.

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.

Vici P, Colucci G, Giotta F, Sergi D, Filippelli G, Perri P, Botti C, Vizza E, Carpino A, Pizzuti L, Latorre A, Giannarelli D, Lopez M, Di Lauro L.

J Exp Clin Cancer Res. 2011 Apr 12;30:39. doi: 10.1186/1756-9966-30-39.

18.

Doxorubicin pathways: pharmacodynamics and adverse effects.

Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB.

Pharmacogenet Genomics. 2011 Jul;21(7):440-6. doi: 10.1097/FPC.0b013e32833ffb56. No abstract available.

19.

Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.

Geisberg CA, Sawyer DB.

Curr Hypertens Rep. 2010 Dec;12(6):404-10. doi: 10.1007/s11906-010-0146-y.

20.

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.

Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A.

BMC Cancer. 2010 Jun 29;10:337. doi: 10.1186/1471-2407-10-337. Review.

Supplemental Content

Support Center